Skip to main content
Clinical Trials/NCT04932213
NCT04932213
Completed
Phase 3

Comparison of the Effect of Tropicamide 0.5% and Tropicamide 1% on Intraocular Pressure, Pupil Size, Keratometry and Anterior Chamber Parameters in Patients With Type 1 and Type 2 Diabetes Mellitus

Semnan University of Medical Sciences1 site in 1 country98 target enrollmentJuly 7, 2021

Overview

Phase
Phase 3
Intervention
Tropicamide Ophthalmic
Conditions
Type 2 Diabetes Mellitus
Sponsor
Semnan University of Medical Sciences
Enrollment
98
Locations
1
Primary Endpoint
Change from baseline in Intraocular pressure (IOP)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The aim of this study is to compare the effect of tropicamide 0.5% and tropicamide 1% on intraocular pressure and anterior chamber parameters in patients with Diabetes Mellitus.

Detailed Description

Patients with diabetes type 1 and type 2 older than 21 years of age, in the specialized clinic of Kowsar Hospital (Semnan University of Medical Sciences) are examined. Eligible individuals enter the study and are randomly assigned to group 1 or group 2. In each group, visual acuity measurement, slit lamp biomicroscopy and fundus examination are performed. Intraocular pressure is measured with Goldmann applanation tonometer. pupil size, refraction and keratometry are measured with two different autorefractokeratometers. keratometry, pupil size and other anterior chamber parameters are also evaluated by Oculus Pentacam imaging. Then, the patients receive tropicamide 0.5% drops in group 1 and tropicamide 1% drops in group 2. 30 minutes later, all previous measurements are repeated. Patients and the ophthalmologist and the data analyzer are unaware of the drug type.

Registry
clinicaltrials.gov
Start Date
July 7, 2021
End Date
November 7, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Semnan University of Medical Sciences
Responsible Party
Principal Investigator
Principal Investigator

Navid Elmi Sadr

Assistant professor of ophthalmology

Semnan University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Patients with Diabetes Mellitus type 1 and 2

Exclusion Criteria

  • Proliferative diabetic retinopathy
  • History of cataract surgery
  • severe nuclear and cortical cataract
  • Intraocular pressure (IOP) greater than 21 mmHg
  • Familial history of glaucoma
  • Narrow angle (Van Herick 1, 2)
  • Cup to disc ratio greater than 0.5
  • Pregnancy
  • Pterygium
  • Corneal ectasia

Arms & Interventions

Tropicamide 0.5%

This group receives tropicamide 0.5% (one drop every 5 minutes for 2 times) drops.

Intervention: Tropicamide Ophthalmic

Tropicamide 1%

This group receives tropicamide 1% (one drop every 5 minutes for 2 times) drops.

Intervention: Tropicamide Ophthalmic

Outcomes

Primary Outcomes

Change from baseline in Intraocular pressure (IOP)

Time Frame: Before intervention, 30 minutes after intervention

The intraocular pressure is measured by Goldmann applanation tonometry

Change from baseline in pupillary diameter

Time Frame: Before intervention, 30 minutes after intervention

The diameter of the participants' pupil is measured by Scheimpflug camera (Oculus Pentacam); Autorefractokeratometer (TOMEY RC-5000 and Topcon KR-1)

Secondary Outcomes

  • Change from baseline in anterior chamber angle (ACA)(Before intervention, 30 minutes after intervention)
  • Change from baseline in central corneal thickness (CCT)(Before intervention, 30 minutes after intervention)
  • Change from baseline in Keratometry(Before intervention, 30 minutes after intervention)
  • Change from baseline in anterior chamber depth (ACD)(Before intervention, 30 minutes after intervention)
  • Change from baseline in anterior chamber volume (ACV)(Before intervention, 30 minutes after intervention)

Study Sites (1)

Loading locations...

Similar Trials